Download PDFPDF

Original research
Analysis of belimumab prescription and outcomes in a 10-year monocentric cohort: is there an advantage with early use?
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • A rapid response is a moderated but not peer reviewed online response to a published article in a BMJ journal; it will not receive a DOI and will not be indexed unless it is also republished as a Letter, Correspondence or as other content. Find out more about rapid responses.
  • We intend to post all responses which are approved by the Editor, within 14 days (BMJ Journals) or 24 hours (The BMJ), however timeframes cannot be guaranteed. Responses must comply with our requirements and should contribute substantially to the topic, but it is at our absolute discretion whether we publish a response, and we reserve the right to edit or remove responses before and after publication and also republish some or all in other BMJ publications, including third party local editions in other countries and languages
  • Our requirements are stated in our rapid response terms and conditions and must be read. These include ensuring that: i) you do not include any illustrative content including tables and graphs, ii) you do not include any information that includes specifics about any patients,iii) you do not include any original data, unless it has already been published in a peer reviewed journal and you have included a reference, iv) your response is lawful, not defamatory, original and accurate, v) you declare any competing interests, vi) you understand that your name and other personal details set out in our rapid response terms and conditions will be published with any responses we publish and vii) you understand that once a response is published, we may continue to publish your response and/or edit or remove it in the future.
  • By submitting this rapid response you are agreeing to our terms and conditions for rapid responses and understand that your personal data will be processed in accordance with those terms and our privacy notice.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Is early use of belimumab in systemic lupus erythematosus really advantageous?
    • I Rua-Figueroa, Rheumatologist Consultat University Hospital of Gran Canaria Doctor Negrin

    Dear Editor,

    Tani et al. conducted an interesting retrospective analysis, involving a monocentric cohort of patients with systemic lupus erythematosus (SLE) treated with belimumab (BEL), in an attempt to assess outcomes associated with the “early use” of BEL compared to more routinely used, e.g., after immunosuppressors 1. However, this study displays several types of bias and other limitations, which are not sufficiently discussed by the authors.
    First at all, the term “early use”, such as appears in the title of the original, is a bit confusing, since the duration of the disease was 10.1±8.6 years, without significant differences between the groups under comparison. In fact, the original study by Tani et al. is more focused on naïve immunosuppressors versus non IS-naïve ones. The relatively long duration of the disease in the IS-naïve group strongly suggests that it was composed of non-severe patients. The numerically greater number of nephritis cases in the non IS-naïve group, namely 13/80 (16%) vs 1/22 (8%), though not showing any statistically significant difference, reinforces our hypothesis. In this sense, the variables included in the comparison are not enough to conclude that there were no differences in severity between the two groups, especially in light of the fact that SLEDAI is a poor measure of SLE severity. These features make the groups quite difficult to compare, particularly taking into account the small – in fact, very small – sample size...

    Show More
    Conflict of Interest:
    None declared.